Why Men Get Cancer More Often Than Women: What the Research Shows

Across almost every country with reliable cancer records, men are diagnosed with cancer more often than women. This isn't just about cancers tied to reproductive organs, which obviously differ by sex. Even after removing those from the count, men still face a higher overall rate of new cancer diagnoses, a measure researchers call the incidence rate. The gap has been documented for decades, but only in the last fifteen years or so has science started to explain why it exists.

How Big Is the Gap, and Where Does It Show Up Most?

The size of the male-female gap isn't the same across all cancers. For some cancer types it's barely noticeable. For others, men are diagnosed at several times the rate of women. Large-scale analyses of cancer registry data have found that bladder cancer, esophageal cancer, and liver cancer are among the cancers with the widest gap between sexes, with men affected far more often than women even when known risk factors are taken into account. Other cancers, including many of the most common types, show smaller but still consistent male excess.

This unevenness is itself a clue. If the explanation were something simple and uniform, like men simply being bigger or living longer on average, the gap would look roughly similar across cancer types. Instead, it varies widely, which points toward multiple, cancer-specific mechanisms rather than one universal cause.

Lifestyle and Exposure Explain Some of It, But Not All

Part of the story is straightforward. Men have historically smoked more, consumed more alcohol, and worked in jobs with higher exposure to industrial carcinogens than women, and all three are established drivers of cancer risk. A detailed 2022 analysis that modeled how much of the sex gap these factors could account for found that they explain a meaningful share of the disparity for some cancers, particularly those strongly tied to tobacco and alcohol.

But the same analysis found that known behavioral and environmental risk factors leave much of the gap unexplained, especially for cancers like liver and bladder cancer. In other words, even a man and a woman with identical smoking histories, drinking habits, and occupational exposures would not be expected to carry exactly the same cancer risk. Something beyond behavior is contributing, and that something appears to be rooted in basic biology: the chromosomes, hormones, and immune systems that differ between men and women from birth.

A Hidden Advantage Carried on the X Chromosome

One clue lies in a basic quirk of female genetics. Women carry two X chromosomes, while men carry one X and one Y. Early in development, one of a woman's two X chromosomes is mostly switched off in each cell, a process called X-inactivation, so that women don't end up with double the normal dose of X-linked genes. But the switch-off is incomplete. A number of genes manage to stay active on both copies, effectively escaping inactivation.

This matters because several important tumor suppressor genes, the genes that normally act as brakes on abnormal cell growth, sit on the X chromosome. Research mapping these escaping genes found that women may carry a working backup copy of certain tumor suppressors that men simply don't have, since men only have one X chromosome to begin with. Think of it like having a spare key to a lock: if one copy of the gene is damaged or silenced, the second copy can sometimes still do the job. Men, with only one X chromosome, don't get that backup.

What Happens When Men Lose Part of Their Y Chromosome

The Y chromosome has its own story, and it's one that unfolds with age. As men get older, a surprisingly common change occurs in some of their blood cells: a portion of cells lose their Y chromosome entirely. This is known as mosaic loss of chromosome Y, or mLOY, because only a fraction, not all, of a man's cells are affected.

Work led by geneticist Jan Dumanski's group first showed that men with higher levels of this Y chromosome loss in their blood had shorter survival and a notably higher risk of being diagnosed with cancer, across several cancer types, compared to men whose blood cells retained the Y chromosome. A related study from the same research network found that smoking, one of the few modifiable factors linked to the phenomenon, was itself associated with higher rates of Y chromosome loss. Together, these findings suggest that mLOY may be a biological marker of accelerated aging in blood cells, one that happens to be unique to men simply because women don't have a Y chromosome to lose.

Hormones, Inflammation, and the Immune System

Sex hormones also leave fingerprints on cancer risk well outside the reproductive organs. In laboratory studies of liver cancer, male sex hormones were found to promote the production of an inflammatory signaling molecule called IL-6 through a pathway tied to androgen receptor signaling, the cellular communication system that male hormones like testosterone switch on. Research from Michael Karin's laboratory showed that this hormone-driven inflammation helped explain why liver cancer developed more often and more aggressively in male mice than in female mice. Estrogen, by contrast, appeared to dampen this same inflammatory pathway, offering a plausible mechanism for why human liver cancer also shows a strong male bias.

The immune system itself behaves differently between the sexes in ways that may extend protection beyond the liver. Women generally mount stronger innate and adaptive immune responses than men, a pattern thought to be partly rooted in the extra dose of certain X-linked immune genes that escape inactivation. Because immune surveillance, the body's routine patrolling for abnormal or cancerous cells, depends heavily on these same immune pathways, a more vigilant immune system could help explain part of why women are diagnosed with fewer non-reproductive cancers overall.

Does Sex Also Affect How Treatment Works?

These biological differences don't necessarily stop mattering once cancer is diagnosed. A systematic review and meta-analysis of immunotherapy trials found that the benefit of these treatments differed somewhat between men and women, though the pattern was not consistent across every cancer type or every drug studied. This doesn't mean one sex responds poorly to immunotherapy. It means the size of the benefit, on average across the studies reviewed, wasn't identical between groups. Researchers are still working out which biological factors, including the immune differences described above, might account for this.

A Pattern With Many Contributing Threads

Broader reviews of cancer biology describe sex differences that reach beyond hormones and chromosomes alone, touching basic cell signaling and metabolic pathways that operate differently in male and female cells from the earliest stages of development. This fits with a wider pattern seen across human disease: genetic architecture itself, the underlying structure of how genes relate to disease risk, often differs by sex in ways that reflect deep evolutionary and genomic distinctions between males and females, not just hormone exposure in adulthood.

None of this means a given man is guaranteed to develop cancer, or that a given woman is protected from it. These are population-level patterns, not individual predictions, and plenty of exceptions exist, including men who develop breast cancer and women who develop cancers more typically associated with men. What the evidence does show is that the cancer gap between men and women isn't a single puzzle with one answer. It's a layered one, built from genetics present at conception, hormonal signaling across a lifetime, immune function, and the separate influence of behavior and environment, with researchers still working out exactly how these threads intersect for each cancer type.